Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Pharmaceuticals Ltd.

www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Ltd.

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.

Manufacturing Regulation

Glenmark Has Russian Nod For Rhinitis Drug Montlezir

Glenmark has received a Russian nod to sell its Montlezir tablet for treating allergic rhinitis, further building its presence in the country’s respiratory segment.

Regulation Russian Federation

Glenmark Has An Orphan Ahead of Innovation Capital Raising Plan

FDA orphan drug designation for Glenmark’s multiple myeloma candidate is seen as an important milestone ahead of its innovation spin out’s plans to raise capital in the US to fund pipeline development.

Research & Development India

Novartis Takes Piqray To India With Affordability Pledge

Novartis’s breast cancer therapy Piqray is endorsed by an expert panel for marketing in India and the Swiss company has emphasized its commitment to value-based pricing for the product.

Policy & Regulation India
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register